

Supplementary material

A pragmatic RCT of FF/UMEC/VI in patients with uncontrolled asthma: PERFORM protocol

Stephen G. Noorduyn^{1,2}, Nicola Brown³, Jodie Crawford⁴, Lydia Demetriou; ORCID ID: 0009-0004-4665-279X⁵, Afisi S. Ismaila; ORCID ID: 0000-0002-2876-8308^{1,6}, Lawrence Mbuagbaw; ORCID ID: 0000-0001-5855-5461¹, Sameer Parpia; ORCID ID: 0000-0002-9407-5622¹, Behnam Sadeghirad; ORCID ID: 0000-0001-9422-5232⁷, David Slade⁸, Alison C. Moore⁹

¹Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; ²Global Real-World Evidence, GSK, Mississauga, ON, Canada; ³Clinical Research & Early Programs, GSK, London UK; ⁴Development Biostatistics, GSK, London, UK; ⁵GSK, Stevenage, UK; ⁶Value Evidence and Outcomes, GSK, Collegeville, PA, USA; ⁷Department of Anesthesia, McMaster University, Hamilton, ON, Canada; ⁸Respiratory Clinical Research Unit, GSK, Collegeville, PA, USA; ⁹Global Medical Affairs, General Medicines, GSK, London UK


Corresponding author: Stephen G. Noorduyn, Global Real-World Evidence, GSK, 100 Milverton Drive, Suite 800, Mississauga, ON, Canada, L5R 4H1; Email: stephen.g.noorduyn@gsk.com

17 **Table S1.** Ethics committee approvals of the PERFORM protocol.

Ethics committee	Reference number
Australia	
Bellberry Human Research Ethics Committee	2024-01-106
Japan	
Medical Corporation Shintokai Yokohama Minoru Clinic IRB	N/A
Yamauchi Clinic IRB	
Suzuki Internal & Circulatory Medical Clinic IRB	
Japan Conference of Clinical Research IRB	
Japan Organization of Occupational Health and Safety Kobe Rosai Hospital IRB	
Yoyogi Mental Clinic IRB	
Review Board of Human Rights and Ethics for Clinical Studies IRB	
Kondo Memorial Medical Foundation Tomisaka Clinic IRB	
Teikyo University Hospital IRB	R24-454
Kumamoto University Hospital IRB	2024011
Showa Medical University Hospital IRB	2411004
Aso Iizuka Hospital IRB	45383
Hospital of the University of Occupational and Environmental Health, Japan IRB	10556
Korea	
Kosin University Gospel Hospital IRB	2024-06-009
Hanyang University Seoul Hospital IRB	2024-03-024
Seoul National University Bundang Hospital IRB	B-2409-925-402
Seoul National University Hospital IRB	H-2404-114-1532
Korea University Anam Hospital IRB	N/A
Ewha Womans University Seoul Hospital IRB	2024-03-031
Kyungpook National University Chilgok Hospital IRB	219912/2024-04-044-004
SMG-SNU Boramae Medical Center IRB	30-2024-57
Ajou University Hospital HRPC (Human Research Protection Center).	AJOUIRB-CT-2024-450
Konkuk University Medical Center IRB	KUMC2024-04-045


Taiwan	
China Medical University Hospital Research Ethics Committee	CMUH113-REC3-089
National Taiwan University Hospital Research Ethics Committee	202405036MSC
IRB of Taichung Veterans General Hospital	SC24270B
Kaohsiung Medical University Chung-Ho Memorial Hospital IRB	KMUHIRB-F(I)-20240115
Argentina	
Comité de Ética Dr. Claude Bernard	GSK219912.20240610.13.PI GSK219912.20240527.02.PI
Comité Institucional de Ética de Investigación en Salud Prof. Dr. Marcelino Ruscullada	219912
Comité de Ética en Investigación Hospital Alta Complejidad en Red El Cruce NCK	N/A
Comité de Ética de CER Investigaciones Clínicas	
Investigaciones en Alergia y Enfermedades Respiratorias (INAER) – Comité de Ética en Investigación	
Comité de Ética en Investigación Instituto Ave Pulmo – Fundación Enfisema	
Comité de Bioética - CIMEL	
Comité de Ética en Investigación FUMELIT	
Comité de Ética del Centro de Osteopatías Médicas	
Comité de Ética en Investigación de CEMER	
Comité Independiente de Ética para Ensayos en Farmacología Clínica - Fundación de Estudios Farmacológicos y de Medicamentos “Prof. Luis M. Zieher”	
United States	
Advarra IRB	Pro00077371
Canada	
Advarra IRB	Pro00077371

18 IRB, Institutional Review Board; N/A, not available.



- 21 ACQ-5/6/7, Asthma Control Questionnaire 5/6/7; ACT, Asthma Control Test; AE, adverse event;
- 22 AQLQ, Asthma Quality of Life Questionnaire; FF, fluticasone furoate; ICS, inhaled corticosteroid;
- 23 LABA, long-acting β_2 -agonist, OCS, oral corticosteroid; SABA, short-acting β_2 -agonist; SAE, serious
- 24 adverse event; UMEC, umeclidinium; VI, vilanterol; WAPI:Asthma, Work Productivity and Activity
- 25 Impairment questionnaire for Asthma.

26 **Figure S2.** Step-down closed testing to control for type I error rate.



27 *Patients treated with ICS/LABA prior to randomisation; †patients receiving no treatment prior to
28 randomisation.


29 Data from hierarchy steps 1 and 2 to be reported in primary analysis after Week 24 data collection.

30 Data from hierarchy steps 3–5 to be reported in final analysis after Week 52 data collection.

31 ACQ-7, Asthma Control Questionnaire-7; FAS, full analysis set; FEV₁, forced expiratory volume in 1

32 second; ICS, inhaled corticosteroid; LABA, long-acting β_2 -agonist.

33 **Figure S3.** PRECIS-2 wheel rating how explanatory or pragmatic each domain of the PERFORM trial design is considered to be.



Domain	Average rating
Eligibility: Who is selected to participate in the trial?	4.1
Recruitment: How are participants recruited into the trial?	3.9
Setting: Where is the trial being done?	3.5
Organisation: What expertise and resources are needed to deliver the intervention?	4.5
Flexibility: delivery: How should the intervention be delivered?	4.1
Flexibility: adherence: What measures are in place to make sure the participants adhere to the interventions?	4.3
Follow-up: How closely are the participants followed-up?	4.0
Primary outcome: How relevant is it to participants?	3.7
Primary analysis: To what extent are all data included?	3.9